Navitoclax

Navitoclax (ABT-263) is a potent and orally active Bcl-2 family protein inhibitor that binds to multiple anti-apoptotic Bcl-2 family proteins, such as Bcl-xL, Bcl-2 and Bcl-w, with a Ki of less than 1 nM[1].

Product Specifications

CAS Number

[923564-51-6]

Product Name Alternative

ABT-263

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

Bcl-2 Family

Type

Reference compound

Related Pathways

Apoptosis

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/navitoclax.html

Purity

99.97

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

O=S(C1=CC(S(NC(C2=CC=C(N3CCN(CC4=C(CCC(C)(C4)C)C5=CC=C(Cl)C=C5)CC3)C=C2)=O)(=O)=O)=CC=C1N[C@H](CCN6CCOCC6)CSC7=CC=CC=C7)(C(F)(F)F)=O

Molecular Formula

C47H55ClF3N5O6S3

Molecular Weight

974.61

Precautions

H302, H315, H319, H335

References & Citations

[1]Lock R1, et al. Initial testing (stage 1) of the BH3 mimetic ABT-263 by the pediatric preclinical testing program. Pediatr Blood Cancer. 2008 Jun;50 (6) :1181-1189.|[2]Wong M, et al. Navitoclax (ABT-263) reduces Bcl-x (L) -mediated chemoresistance in ovarian cancer models.Mol Cancer Ther. 2012 Apr;11 (4) :1026-1035.|[3]Chen J, et al. The Bcl-2/Bcl-X (L) /Bcl-w inhibitor, navitoclax, enhances the activity of chemotherapeutic agents in vitro and in vivo. Mol Cancer Ther. 2011 Dec;10 (12) :2340-9.